Ipsen says Phase IIIb trial shows IQIRVO normalizes alkaline phosphatase in 85% of PBC patients vs 23% on placebo

• Ipsen reported Phase IIIb ELSPIRE met its primary endpoint in primary biliary cholangitis, lifting alkaline phosphatase normalization to 85% vs 23% placebo.
• Result was measured at week 52 in patients with alkaline phosphatase 1 to 1.67 times the upper limit of normal.
• Safety profile matched prior data, with no new safety signals identified.
• Plans to present the data at a medical meeting, with regulatory submissions to follow.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ipsen SA published the original content used to generate this news brief on July 13, 2026, and is solely responsible for the information contained therein.